Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Drugs Might Get Hit by SWIFT Ban on Russia Even If Exempted from Trade Sanctions
March 1, 2022
-
BUSINESS Ono Sues AstraZeneca over PD-L1 Patent, Seeks 32 Billion Yen in Damage
March 1, 2022
-
REGULATORY MHLW Approves Label Expansions for Retevmo, Keytruda, Lenvima and More
February 28, 2022
-
ORGANIZATION Impact of Ukraine Invasion Limited in Japan? Trader Group Says Epirubicin Is Only API Possibly Affected
February 25, 2022
-
BUSINESS Tokyo Court Rejects Chugai’s Claim over Edirol Substance Patent
February 25, 2022
-
BUSINESS Medicago’s COVID-19 Vaccine Approved in Canada
February 25, 2022
-
ORGANIZATION Chuikyo Payer Rep Wants Category-Based Debate on Adjustment Rate, Prods PMP Cuts in Next Off-Year Revision
February 24, 2022
-
BUSINESS Bayer Gets Eylea Biosame Approval in Japan as It Braces for Biosimilar Debuts
February 22, 2022
-
BUSINESS Sleep Inducer Recalls by Fuji Yakuhin, Tatsumi Kagaku Tied to Tokyo Wholesaler’s Fake API Case
February 21, 2022
-
REGULATORY Japan Weighs Pre-Approval Purchase of Shionogi’s COVID-19 Pill
February 21, 2022
-
BUSINESS Chugai Claims 1st-Ever Title in Japan Pharma Market in 2021 on Brisk Oncologic Performance: IQVIA
February 18, 2022
-
BUSINESS Sawai to Launch Teribone Generic as Court Invalidates Patents; Asahi Kasei to Challenge Ruling
February 17, 2022
-
REGULATORY Japan Approves Slew of Generics towards June Listing; Samsca, Xarelto AGs Too
February 16, 2022
-
BUSINESS Pharma Officials Air Hopes and Concerns as Japan Moves to Enhance Supply Chain for Economic Security
February 15, 2022
-
REGULATORY Japan Snags 10 Million Extra Doses of Pfizer Vaccine
February 15, 2022
-
BUSINESS Chugai Joins Top Ranks in Japan Sales on Ronapreve Boon, Roche Collaboration
February 14, 2022
-
REGULATORY Pfizer’s Paxlovid Contraindicated with Many Medicines, Requires Careful Use
February 14, 2022
-
REGULATORY Japan Approves Pfizer’s Paxlovid, Second Oral COVID-19 Pill
February 10, 2022
-
ORGANIZATION Govt-Industry Arrangement for Drug Supply Survey Hits Rough Waters; FPMAJ Stands Pat on Continued Dialogue
February 10, 2022
-
REGULATORY Chuikyo Issues 2022 Reform Recommendation; Patch Prescription Limit Lowered to 63 Sheets
February 10, 2022
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…